Literature DB >> 25091521

Calcium-sensing receptor sequencing in 21 patients with idiopathic or familial parathyroid disorder: pitfalls and characterization of a novel I32 V loss-of-function mutation.

Auryan Szalat1, Michal Shahar, Shoshana Shpitzen, Boaz Nachmias, Gabriel Munter, David Gillis, Ronen Durst, Dror Mevorach, Eran Leitersdorf, Vardiella Meiner, Haim Rosen.   

Abstract

The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor with a crucial role in calcium homeostasis. Mutations in the CaSR gene may lead to specific parathyroid disorders due to either gain-of-function (autosomal dominant hypercalciuric hypocalcemia; ADHH) or loss-of-function (familial hypocalciuric hypercalcemia; FHH). Our aim was to evaluate CaSR mutations as a cause of disease in selected patients. We identified and recruited patients with phenotypes suggestive of CaSR-related parathyroid disorders. DNA was extracted, and CaSR gene was sequenced. Live-ratiometric measurements of intracellular [Ca(2+)] and Western blot assays for evaluation of MAPK phosphorylation in response to changes in extracellular [Ca(2+)] were performed in transiently transfected HEK-293T cells to functionally characterize mutants. A total of 21 patients were evaluated, seven of them with idiopathic hypoparathyroidism (suspected ADHH) and 14 with hyperparathyroidism (suspected FHH). In the latter group two patients were found to harbor missense mutations: a novel heterozygous I32 V mutation in a female index case and a sporadic known R185Q mutation in a 1-year-old girl. In-vitro functional studies showed that I32 V is an inactivating mutation. In our study, most patients had normal CaSR sequencing. This suggests that phenotypic pitfalls may occur at time of patients' selection for CaSR sequencing. In one patient with strong positive pre-test probability based on both familial history and appropriate phenotype, a novel I32 V mutation leading to FHH was identified and characterized. In cases of familial parathyroid disorders, CaSR sequencing should be performed, but if negative, one should consider involvement of alternative genes or mechanisms.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25091521     DOI: 10.1007/s12020-014-0370-3

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  42 in total

1.  Acquired hypocalciuric hypercalcemia due to autoantibodies against the calcium-sensing receptor.

Authors:  J Carl Pallais; Olga Kifor; Yi-Bin Chen; David Slovik; Edward M Brown
Journal:  N Engl J Med       Date:  2004-07-22       Impact factor: 91.245

Review 2.  Clinical lessons from the calcium-sensing receptor.

Authors:  Edward M Brown
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2007-02

Review 3.  Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations.

Authors:  Ogo I Egbuna; Edward M Brown
Journal:  Best Pract Res Clin Rheumatol       Date:  2008-03       Impact factor: 4.098

4.  Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research.

Authors:  John P Bilezikian; Aliya Khan; John T Potts; Maria Luisa Brandi; Bart L Clarke; Dolores Shoback; Harald Jüppner; Pierre D'Amour; John Fox; Lars Rejnmark; Leif Mosekilde; Mishaela R Rubin; David Dempster; Rachel Gafni; Michael T Collins; Jim Sliney; James Sanders
Journal:  J Bone Miner Res       Date:  2011-10       Impact factor: 6.741

5.  Mutations in the human Ca(2+)-sensing-receptor gene that cause familial hypocalciuric hypercalcemia.

Authors:  Y H Chou; M R Pollak; M L Brandi; G Toss; H Arnqvist; A B Atkinson; S E Papapoulos; S Marx; E M Brown; J G Seidman
Journal:  Am J Hum Genet       Date:  1995-05       Impact factor: 11.025

6.  Autoimmune hypocalciuric hypercalcemia unresponsive to glucocorticoid therapy in a patient with blocking autoantibodies against the calcium-sensing receptor.

Authors:  J Carl Pallais; E Helen Kemp; Clemens Bergwitz; Lakshmi Kantham; David M Slovik; Anthony P Weetman; Edward M Brown
Journal:  J Clin Endocrinol Metab       Date:  2010-12-15       Impact factor: 5.958

7.  Agonists of the Ca(2+)-sensing receptor (CaR) activate nonselective cation channels in HEK293 cells stably transfected with the human CaR.

Authors:  C Ye; K Rogers; M Bai; S J Quinn; E M Brown; P M Vassilev
Journal:  Biochem Biophys Res Commun       Date:  1996-09-13       Impact factor: 3.575

8.  Prevalence of calcium sensing receptor autoantibodies in patients with sporadic idiopathic hypoparathyroidism.

Authors:  Ravinder Goswami; Edward M Brown; Narayana Kochupillai; Nandita Gupta; Rajni Rani; Olga Kifor; Naibedya Chattopadhyay
Journal:  Eur J Endocrinol       Date:  2004-01       Impact factor: 6.664

9.  Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism.

Authors:  M R Pollak; E M Brown; Y H Chou; S C Hebert; S J Marx; B Steinmann; T Levi; C E Seidman; J G Seidman
Journal:  Cell       Date:  1993-12-31       Impact factor: 41.582

10.  Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen.

Authors:  Mohammad Alimohammadi; Peyman Björklund; Asa Hallgren; Nora Pöntynen; Gabor Szinnai; Noriko Shikama; Marcel P Keller; Olov Ekwall; Sarah A Kinkel; Eystein S Husebye; Jan Gustafsson; Fredrik Rorsman; Leena Peltonen; Corrado Betterle; Jaakko Perheentupa; Göran Akerström; Gunnar Westin; Hamish S Scott; Georg A Holländer; Olle Kämpe
Journal:  N Engl J Med       Date:  2008-03-06       Impact factor: 91.245

View more
  3 in total

1.  Stepwise CaSR, AP2S1, and GNA11 sequencing in patients with suspected familial hypocalciuric hypercalcemia.

Authors:  Auryan Szalat; Shoshana Shpitzen; Anat Tsur; Ilana Zalmon Koren; Shmuel Shilo; Liana Tripto-Shkolnik; Ronen Durst; Eran Leitersdorf; Vardiella Meiner
Journal:  Endocrine       Date:  2017-02-07       Impact factor: 3.633

2.  Identification and Functional Characterization of a Calcium-Sensing Receptor Mutation in an Infant with Familial Hypocalciuric Hypercalcemia.

Authors:  Anna Papadopoulou; Evangelia Gole; Katerina Melachroinou; Christos Meristoudis; Tania Siahanidou; Anastasios Papadimitriou
Journal:  J Clin Res Pediatr Endocrinol       Date:  2016-04-18

3.  Prenatal features and neonatal management of severe hyperparathyroidism caused by the heterozygous inactivating calcium-sensing receptor variant, Arg185Gln: A case report and review of the literature.

Authors:  Marion Aubert-Mucca; Charlotte Dubucs; Marion Groussolles; Julie Vial; Edouard Le Guillou; Valerie Porquet-Bordes; Eric Pasmant; Jean-Pierre Salles; Thomas Edouard
Journal:  Bone Rep       Date:  2021-06-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.